Search Results

; 45 : 1206 – 1213 . 11. De Mitri MS Poussin K Baccarini P . HCV-associated liver cancer without cirrhosis . Lancet 1995 ; 345 : 413 – 415 . 12. Bralet MP Regimbeau JM Pineau P . Hepatocellular carcinoma occurring in

. Lancet 1978 ; 1 : 1006 – 1009 . 12 Williams R Melia WM . Liver tumours and their management . Clin Radiol 1980 ; 31 : 1 – 11 . 13 Barbare JC Ballet F Petit J . [Hepatocellular carcinoma with cirrhosis: treatment with

– 96 . 2 Fattovich G Stroffolini T Zagni I Donato F . Hepatocellular carcinoma in cirrhosis: incidence and risk factors . Gastroenterology 2004 ; 127 ( 5 Suppl 1 ): S35 – 50 . 3 Bosch FX Ribes J Borras J . Epidemiology of

cancer treatment complicated. 16 In addition, successful HCV therapy can cure HCV, prevent its reactivation, 17 delay progression to cirrhosis, 12 – 14 and improve overall mortality rates, as observed in the general population of HCV-monoinfected and

Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related death worldwide and one of the leading causes of death among patients with cirrhosis. It has an increasing incidence in the United States because of the current epidemics

hepatocellular carcinoma in cirrhotic patients . Ann Surg 1993 ; 218 : 145 – 151 . 8. Mazzaferro V Regalia E Doci R . Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis . N Engl J Med 1996 ; 334

areas, development of cirrhosis in patients who were infected with hepatitis C virus (HCV) in the 1970s and 1980s, as well as the increase in nonalcoholic fatty liver disease. 2 As Dr. Covey pointed out, the incidence of disease parallels that of

cirrhosis . N Eng J Med 1996 ; 334 : 693 – 699 . 8 Jonas S Bechstein WO Steinmuller T . Vascular invasion and histopathologic grading determine outcome after liver transplantation for hepatocellular carcinoma in cirrhosis . Hepatology 2001

only available for patients diagnosed at an early stage. 2 Surveillance at 6-month intervals is recommended in patients with cirrhosis to detect HCC at an early stage. 3 Despite the availability of efficacious surveillance tests, only 40% of patients

cirrhosis and most have multifocal cancer, both of which limit treatment options. 2 , 3 Two intra-arterially delivered locoregional therapy (LRT) options are considered to be reasonable initial therapy for patients with unresectable HCC and compensated